SC
FATE icon

Schulhoff & Co’s Fate Therapeutics FATE Stock Holding History

Schulhoff & Co’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$120K Buy
+100,000
New +$122K 0.05% 132

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Schulhoff & Co's FATE Position: Q1 2026 in Review

Schulhoff & Co opened a new position in Fate Therapeutics (FATE) in Q1 2026: 100,000 shares worth $120K. The stake represents 0.05% of the portfolio and ranks #132 among its holdings.

157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Schulhoff & Co held 100,000 shares of Fate Therapeutics worth $120K as of Q1 2026.
  • Fate Therapeutics was a new Schulhoff & Co position in Q1 2026.
  • Fate Therapeutics made up 0.05% of Schulhoff & Co's portfolio in Q1 2026, its #132 holding.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Schulhoff & Co's 13F filing for Q1 2026, filed 11 May 2026.